Current care pathway for the management of psychosis Martin Livingston MD, FRCPsych
The management of psychotic disorders is a community-based collaboration between primary and secondary care. Our Drug review outlines the general care pathway and potential treatment problems, followed by an analysis of the prescription data.
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Early intervention
A long duration of untreated psychosis (DUP) is recognised as a poor prognostic factor 5 and services now try to encourage early referral, especially in young people in a first episode before florid illness develops. This has led to the development of early intervention in psychosis teams consisting of psychiatrists, psychologists, nurses, healthcare assistants and occupational therapists, all of whom link with GP services. There is often a formalised link with primary care not just to share mental health care but also to ensure that patients have good access to treatment for physical health problems. Severe enduring mental illness results in a reduced life span of up to 20 years. Despite a Quality and Outcomes Framework (QOF) requirement for regular monitoring of body mass index (BMI), BP, cholesterol and blood glucose, patients who suffer from a psychotic disorder often fail to attend their GPs. Services aim to manage patients in the community but there is still, at times, a need for inpatient facilities that are nonstigmatising and attuned to the needs of the population to be treated, eg young persons in a first episode.
Prodromal illness
The characteristics of a prodromal phase of psychosis include impaired self-care, difficulties with concentration, memory and communicating as well as an altered mood state, typically depressive. These symptoms are relatively non-specific and diagnosis of a specific psychosis such as schizophrenia is usually not feasible at this stage. Patients should be investigated for substance misuse. Relatives or other close associates are often very helpful in making a diagnosis as they may have recognised a distinct change in the patient's behaviour and may of course have prompted the referral to secondary care services.
Some early intervention programmes have advocated rapid initiation of antipsychotic medication to prevent the onset of a clearly diagnosable psychosis. But NICE, on reviewing the available studies, concluded that antipsychotic medication was no more effective than psychological interventions or placebo in preventing this transition. 6 Deciding when to intervene in an early stage, and with what, is a decision that requires careful consideration by multidisciplinary teams, patients and their carers. Early intervention teams offer intensive psychological and social approaches to management in addition to drug therapy, where required, typically for periods of around two years before handing over care in those with ongoing mental health problems to the community mental health team. 
Community mental health teams
Since the 1970s the balance between hospital and community care has shifted dramatically in the direction of the latter. Community mental health teams (CMHTs) usually offer a similar range of disciplinary input as the early intervention teams. They are succeeding in transforming the lives of people with psychosis, enabling fuller functioning in the community. Once a diagnosis has been established, and treatment in the early intervention team concluded, the CMHT aims to manage the transition from that service and to provide a multidisciplinary-based comprehensive care package. The services of such teams may be further specialised into groupings such as crisis intervention (providing short-term intensive therapeutic input) and assertive outreach (for people who have more complex needs, have severe illnesses, and do not engage well with services).
Psychosocial treatment programmes and the recovery model
Many people who suffer from schizophrenia and related psychoses live in urban environments in the UK where there is poor housing and multiple social problems including drug and alcohol addiction. They may be exposed to stigma about their illness and high levels of expressed negative emotion. Psycho-educational programmes try to tackle these issues with patients and their carers and attempt to bolster self-esteem. Additional funding has been made available in England and Wales to provide psychological therapies for patients with severe mental illness. Increasing awareness of cognitive developmental processes has resulted in the formation of cognitive models of schizophrenia. This knowledge has led to psychologists, or psychologically trained staff from other disciplines such as nursing, attempting to address the vulnerabilities that lead to psychosis. Psychologically-trained staff also help patients and their carers manage the distress associated with the illness, assist them in developing a plan for social and educational recovery and build in relapse prevention strategies.
Patients and their carers may be aware of altered behaviours and feelings that signal the onset of more florid symptoms. Social strategies involve facilitating families and carers to develop supportive approaches to their ill relative. The CMHT will typically advocate more stable lifestyles and give guidance on health issues including diet and avoidance of street drugs. The emphasis is on encouraging the service user to develop and then achieve his or her own recovery goals -the so-called recovery model. Ideally, carers, some of whom quite naturally tend to focus on the burdens, may come to appreciate that caring can be mutually rewarding for carer and the cared person. This is important because as many as 50 per cent of people with schizophrenia have contact with a close relative, of whom two thirds are female. Although there is limited evidence that treatments outlined in the recovery model eradicate symptoms, the key aim is to assist the patient and his/her carers in living with an illness that may have a profound impact on their lives.
Pharmacotherapy
For the majority of patients with a frank psychotic illness, antipsychotic drug treatment is essential in the acute phase and is likely to be required indefinitely to prevent recurrence. The choice of an antipsychotic should be based on an individual patient's needs, for example, whether a high level of sedation is required, weight gain is to be avoided, or adherence enhanced by use of a once-daily regimen, or a rapid-release formulation such as those for olanzapine (Zyprexa Velotab) and risperidone (Risperdal Quicklet) or a long-acting injectable antipsychotic. There are now n DRUG REVIEW l Psychosis 20 z Prescriber December 2014 prescriber.co.uk four long-acting injectable second-generation antipsychotics (SGAs) offering a choice to prescribers of frequency of dosing, dose initiation regimens and injection sites (see Table 2 ). There is a major practical difficulty with olanzapine embonate (Zypadhera) due to the presence of a post-injection syndrome, which necessitates monitoring of the patient's BP, pulse and respiratory rate for at least four hours post-injection. Interactions with other medications should also be considered. As antipsychotics often have multiple pharmacodynamic actions there are many possibilities for drug-drug interaction. The BNF is helpful in setting out the more critical interactions. All antipsychotic drugs, whether first or second generation, are dopamine antagonists blocking D 2 post-synaptic receptors in the mesolimbic area of the brain. This observation supports the dopamine hypothesis of the causation of schizophrenia, and possibly other psychoses. This hypothesis theory was first outlined in the 1960s. It is recognised that it provides only a partial explanation.
Choosing an antipsychotic
Meta-analyses have tended not to support the contention that, as a group, the newer SGAs are superior in antipsychotic efficacy to the first generation antipsychotics (FGAs). 7 There are, however, some differences in the efficacy profiles of the drugs. While clozapine stands out as the only antipsychotic drug indicated for treatment-refractory schizophrenia, amisulpride, in this meta-analysis, did appear to have some efficacy advantages over the rest of the antipsychotic medications studied. Fewest patients discontinued treatment with amisulpride, clozapine caused fewest extra-pyramidal side-effects (EPS), and olanzapine caused most weight gain. Antipsychotics are more effective against positive symptoms, less so in treating negative symptoms and cognitive impairments. These differences present useful treatment options guiding the choice of antipsychotic. Although higher doses may be required in an acute, floridly psychotic phase, there is little evidence to support supra-BNF dosing. The Royal College of Psychiatrists has issued guidelines outlining the risk of such high-dose regimens and how to monitor them to minimise risk. 8 Lower doses of medication are often used, at least initially, in early intervention programmes where florid psychotic phenomena have begun to emerge. A useful maxim is 'start low and go slow', recognising that this is not always possible when the patient is very disturbed.
The side-effects of antipsychotics include EPS, weight gain, postural hypotension, prolongation of the QT interval, undesired sedation, sexual dysfunction, metabolic abnormalities such as elevated blood glucose and lipids, and increased prolactin secretion (see Table 3 ). The use of multiple antipsychotics should be avoided and side-effects are best treated by dose reduction or switching. If this is not feasible anticholinergic agents (eg orphenadrine and procyclidine) may counter drug-induced tremor and immobility as well as dystonias. Beta-blockers such as propranolol are useful in treating the restlessness and agitation of akathisia. Due to these side-effects monitoring of weight and BMI, blood pressure, plasma glucose and lipids, prolactin and liver function is recommended on initiation and at least annually. An ECG should be taken at initiation of drug treatment, following switching to a drug such as haloperidol or pimozide (Orap) at higher risk of prolonging the QT interval or if using a high dose regimen.
The only antipsychotic for which superiority in treatment-resistant cases of schizophrenia has been clearly demonstrated is clozapine. 9 This is the case despite its low occupancy of D 2 receptor sites. Due to the 3-4 per cent risk of neutropenia, which is potentially fatal, clozapine is reserved for treatment-resistant schizophrenia, non-responsive psychosis in Parkinson's disorder and other neurological diseases. Treatment resistance is defined as an inadequate response to two or more antipsychotics. The haematological profile of the patient has to be monitored in a prescribed programme. This involves a blood screen weekly for the first 18 weeks, then fortnightly for the rest of the year, monthly thereafter. In addition to being more effective than other antipsychotics, clozapine reduces the risk of suicide. It is important to bear in mind that the rate of suicide in schizophrenia is around 5 per cent. 10 A wide range of neurotransmitters are involved in clozapine's spectrum of activity -D 2, D 3 , D 4 , 5-HT 2 , 5-HT 6 and 5-HT 7 . Although some of these may be implicated in the causation of schizophrenia and other psychoses, knowledge of clozapine's spectrum of activity has, to date, not led to the development of alternative, safer antipsychotics with clozapine-like efficacy in treatment-resistant schizophrenia.
Conclusions
Treating psychotic disorders is now mainly community based involving a collaboration between primary-and secondary-care services. The general care pathway is outlined in Figure 1 and involves multidisciplinary programmes integrating a wide range of drug treatment options with psychosocial therapies. Patients and their carers are encouraged to establish their own goals for treatment.
